{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000022","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.672624+00:00","generated_at":"2026-06-07T02:58:56.167407+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunic announces private placement of up to $240M; first $80M tranche closes Jan 8","bullets":["First tranche $80M at $1.43/share to close Jan 8, 2024; lead investor BVF Partners.","Second tranche mandatory $80M at $1.716/share conditional on Phase 2b topline data for vidofludimus calcium in PMS (April 2025) and stock price/volume thresholds.","Third tranche up to $80M at same price but cashless settlement possible; total gross proceeds $80M–$240M.","Proceeds to fund vidofludimus calcium, IMU-856, and IMU-381 clinical development; first tranche extends cash runway into Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000022","json":"https://secwatch.observer/filing/0001193805-24-000022.json","markdown":"https://secwatch.observer/filing/0001193805-24-000022.md","text":"https://secwatch.observer/filing/0001193805-24-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/0001193805-24-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:58:56.167407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}